Cargando…

574. Antibodies Targeting Candida albicans Als3 and Hyr1 Antigens Protect Neonatal Mice from Candidiasis

BACKGROUND: Pre-term infants in neonatal intensive care units are vulnerable to fungal sepsis. In this patient population, C. albicans remains the predominant fungal pathogen causing high morbidity and mortality, despite antifungal therapy. Thus, new therapeutic strategies against neonatal candidias...

Descripción completa

Detalles Bibliográficos
Autores principales: Singh, Shakti, Nabeela, Sunna, Barbarino, Ashley M, Ibrahim, Ashraf S, Uppuliri, Priya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9752334/
http://dx.doi.org/10.1093/ofid/ofac492.627
_version_ 1784850696478130176
author Singh, Shakti
Nabeela, Sunna
Barbarino, Ashley M
Ibrahim, Ashraf S
Uppuliri, Priya
author_facet Singh, Shakti
Nabeela, Sunna
Barbarino, Ashley M
Ibrahim, Ashraf S
Uppuliri, Priya
author_sort Singh, Shakti
collection PubMed
description BACKGROUND: Pre-term infants in neonatal intensive care units are vulnerable to fungal sepsis. In this patient population, C. albicans remains the predominant fungal pathogen causing high morbidity and mortality, despite antifungal therapy. Thus, new therapeutic strategies against neonatal candidiasis are needed. We have reported that vaccination with C. albicans cell wall N-termini recombinant proteins Als3 (rAls3p-N) and Hyr1 (rHyr1p-N) protected adult mice from disseminated candidiasis. Further, NDV-3A (rAls3p-N+alum) protected women from recurrent vulvovaginal candidiasis, which was correlated with anti-Als3p IgG2 isotype titer. Here, we evaluated the efficacy of Als3p and Hyr1p based vaccine in a neonatal candidiasis mouse model. METHODS: Inbred BALB/c mice strain was used for both active and passive vaccination studies. Female 4-6 weeks old mice were vaccinated with rAls3p-N or rHyr1p-N antigens mixed with complete Freund’s adjuvant (CFA, priming)/incomplete Freund’s adjuvant (IFA, boosting). Mice were mated after the boost and pups (3 days old) born to vaccinated mice were infected intraperitoneally (IP) with C. albicans. For passive vaccination, 3 days old naive pups were IP infected with C. albicans and treated with serum obtained from vaccinated adult mice. Fungal burdens were determined in the kidneys of infected neonate mice at 3 days post-infection. Antibody titers were determined by ELISA. RESULTS: CFA/IFA formulated Als3 and Hyr1 vaccines induced a robust antibody response with a ten-fold higher titer of IgG2, than attained by either antigen formulated with alum. Transplacental transfer of these antibodies significantly reduced the fungal burden in the kidneys of mice pups, and adoptive transfer of vaccinated mothers’ sera into pups displayed similar levels of protection. Neutrophils were found important for this efficacy. Anti-Hyr1 antisera potentiated the activity of fluconazole in protecting from C. albicans infection. CONCLUSION: Our current studies are the first to emphasize the importance of anti-Als3 and anti-Hyr1 antibodies in preventing neonatal candidiasis. Considering that Candida infections in low birth weight infants is a lethal infection, active and passive vaccination strategies using these antigens could have profound clinical significance. DISCLOSURES: All Authors: No reported disclosures.
format Online
Article
Text
id pubmed-9752334
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-97523342022-12-16 574. Antibodies Targeting Candida albicans Als3 and Hyr1 Antigens Protect Neonatal Mice from Candidiasis Singh, Shakti Nabeela, Sunna Barbarino, Ashley M Ibrahim, Ashraf S Uppuliri, Priya Open Forum Infect Dis Abstracts BACKGROUND: Pre-term infants in neonatal intensive care units are vulnerable to fungal sepsis. In this patient population, C. albicans remains the predominant fungal pathogen causing high morbidity and mortality, despite antifungal therapy. Thus, new therapeutic strategies against neonatal candidiasis are needed. We have reported that vaccination with C. albicans cell wall N-termini recombinant proteins Als3 (rAls3p-N) and Hyr1 (rHyr1p-N) protected adult mice from disseminated candidiasis. Further, NDV-3A (rAls3p-N+alum) protected women from recurrent vulvovaginal candidiasis, which was correlated with anti-Als3p IgG2 isotype titer. Here, we evaluated the efficacy of Als3p and Hyr1p based vaccine in a neonatal candidiasis mouse model. METHODS: Inbred BALB/c mice strain was used for both active and passive vaccination studies. Female 4-6 weeks old mice were vaccinated with rAls3p-N or rHyr1p-N antigens mixed with complete Freund’s adjuvant (CFA, priming)/incomplete Freund’s adjuvant (IFA, boosting). Mice were mated after the boost and pups (3 days old) born to vaccinated mice were infected intraperitoneally (IP) with C. albicans. For passive vaccination, 3 days old naive pups were IP infected with C. albicans and treated with serum obtained from vaccinated adult mice. Fungal burdens were determined in the kidneys of infected neonate mice at 3 days post-infection. Antibody titers were determined by ELISA. RESULTS: CFA/IFA formulated Als3 and Hyr1 vaccines induced a robust antibody response with a ten-fold higher titer of IgG2, than attained by either antigen formulated with alum. Transplacental transfer of these antibodies significantly reduced the fungal burden in the kidneys of mice pups, and adoptive transfer of vaccinated mothers’ sera into pups displayed similar levels of protection. Neutrophils were found important for this efficacy. Anti-Hyr1 antisera potentiated the activity of fluconazole in protecting from C. albicans infection. CONCLUSION: Our current studies are the first to emphasize the importance of anti-Als3 and anti-Hyr1 antibodies in preventing neonatal candidiasis. Considering that Candida infections in low birth weight infants is a lethal infection, active and passive vaccination strategies using these antigens could have profound clinical significance. DISCLOSURES: All Authors: No reported disclosures. Oxford University Press 2022-12-15 /pmc/articles/PMC9752334/ http://dx.doi.org/10.1093/ofid/ofac492.627 Text en © The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Abstracts
Singh, Shakti
Nabeela, Sunna
Barbarino, Ashley M
Ibrahim, Ashraf S
Uppuliri, Priya
574. Antibodies Targeting Candida albicans Als3 and Hyr1 Antigens Protect Neonatal Mice from Candidiasis
title 574. Antibodies Targeting Candida albicans Als3 and Hyr1 Antigens Protect Neonatal Mice from Candidiasis
title_full 574. Antibodies Targeting Candida albicans Als3 and Hyr1 Antigens Protect Neonatal Mice from Candidiasis
title_fullStr 574. Antibodies Targeting Candida albicans Als3 and Hyr1 Antigens Protect Neonatal Mice from Candidiasis
title_full_unstemmed 574. Antibodies Targeting Candida albicans Als3 and Hyr1 Antigens Protect Neonatal Mice from Candidiasis
title_short 574. Antibodies Targeting Candida albicans Als3 and Hyr1 Antigens Protect Neonatal Mice from Candidiasis
title_sort 574. antibodies targeting candida albicans als3 and hyr1 antigens protect neonatal mice from candidiasis
topic Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9752334/
http://dx.doi.org/10.1093/ofid/ofac492.627
work_keys_str_mv AT singhshakti 574antibodiestargetingcandidaalbicansals3andhyr1antigensprotectneonatalmicefromcandidiasis
AT nabeelasunna 574antibodiestargetingcandidaalbicansals3andhyr1antigensprotectneonatalmicefromcandidiasis
AT barbarinoashleym 574antibodiestargetingcandidaalbicansals3andhyr1antigensprotectneonatalmicefromcandidiasis
AT ibrahimashrafs 574antibodiestargetingcandidaalbicansals3andhyr1antigensprotectneonatalmicefromcandidiasis
AT uppuliripriya 574antibodiestargetingcandidaalbicansals3andhyr1antigensprotectneonatalmicefromcandidiasis